351 related articles for article (PubMed ID: 19496103)
1. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
Akhondzadeh S; Jafari S; Raisi F; Nasehi AA; Ghoreishi A; Salehi B; Mohebbi-Rasa S; Raznahan M; Kamalipour A
Depress Anxiety; 2009; 26(7):607-11. PubMed ID: 19496103
[TBL] [Abstract][Full Text] [Related]
2. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Müller N; Schwarz MJ; Dehning S; Douhe A; Cerovecki A; Goldstein-Müller B; Spellmann I; Hetzel G; Maino K; Kleindienst N; Möller HJ; Arolt V; Riedel M
Mol Psychiatry; 2006 Jul; 11(7):680-4. PubMed ID: 16491133
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Akhondzadeh S; Tabatabaee M; Amini H; Ahmadi Abhari SA; Abbasi SH; Behnam B
Schizophr Res; 2007 Feb; 90(1-3):179-85. PubMed ID: 17208413
[TBL] [Abstract][Full Text] [Related]
4. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.
Sayyah M; Boostani H; Pakseresht S; Malayeri A
Psychiatry Res; 2011 Oct; 189(3):403-6. PubMed ID: 21329988
[TBL] [Abstract][Full Text] [Related]
5. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.
Musil R; Schwarz MJ; Riedel M; Dehning S; Cerovecki A; Spellmann I; Arolt V; Müller N
J Affect Disord; 2011 Nov; 134(1-3):217-25. PubMed ID: 21684012
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
Asadabadi M; Mohammadi MR; Ghanizadeh A; Modabbernia A; Ashrafi M; Hassanzadeh E; Forghani S; Akhondzadeh S
Psychopharmacology (Berl); 2013 Jan; 225(1):51-9. PubMed ID: 22782459
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial.
Ghanizadeh A; Hedayati A
Depress Anxiety; 2013 Nov; 30(11):1084-8. PubMed ID: 24115188
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
[TBL] [Abstract][Full Text] [Related]
10. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
11. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
Abbasi SH; Hosseini F; Modabbernia A; Ashrafi M; Akhondzadeh S
J Affect Disord; 2012 Dec; 141(2-3):308-14. PubMed ID: 22516310
[TBL] [Abstract][Full Text] [Related]
12. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.
Nemets B; Bersudsky Y; Belmaker RH
J Clin Psychiatry; 2005 May; 66(5):586-90. PubMed ID: 15889944
[TBL] [Abstract][Full Text] [Related]
13. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes.
Barbosa L; Berk M; Vorster M
J Clin Psychiatry; 2003 Apr; 64(4):403-7. PubMed ID: 12716240
[TBL] [Abstract][Full Text] [Related]
14. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
March JS; Silva S; Petrycki S; Curry J; Wells K; Fairbank J; Burns B; Domino M; McNulty S; Vitiello B; Severe J
Arch Gen Psychiatry; 2007 Oct; 64(10):1132-43. PubMed ID: 17909125
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
Schatzberg A; Roose S
Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
[TBL] [Abstract][Full Text] [Related]
16. Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial.
Macías-Cortés Edel C; Llanes-González L; Aguilar-Faisal L; Asbun-Bojalil J
PLoS One; 2015; 10(3):e0118440. PubMed ID: 25768800
[TBL] [Abstract][Full Text] [Related]
17. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
18. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
Davey CG; Chanen AM; Hetrick SE; Cotton SM; Ratheesh A; Amminger GP; Koutsogiannis J; Phelan M; Mullen E; Harrison BJ; Rice S; Parker AG; Dean OM; Weller A; Kerr M; Quinn AL; Catania L; Kazantzis N; McGorry PD; Berk M
Lancet Psychiatry; 2019 Sep; 6(9):735-744. PubMed ID: 31371212
[TBL] [Abstract][Full Text] [Related]
19. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
